Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Minimally invasive transcatheter system for tricuspid heart valve replacement

Project description

First-of-its-kind minimally invasive treatment of the tricuspid heart valve

The tricuspid valve is one of four valves in the heart and is located between the two right chambers. When this valve doesn’t close properly, blood flows backward into the right atrium. Unlike other heart valve diseases that can be treated by transcatheter heart valve replacement and/or repair, tricuspid valve disease requires open-heart surgery, but the majority of patients are not suitable for such a high-risk procedure. To address this problem, the EU-funded TRICARIX project has developed an innovative device that can be implanted through a minimally invasive procedure offering a viable treatment option for millions of people worldwide.

Objective

TRiCares is a medical technology company with the mission to develop and commercialize innovative minimally invasive (transcatheter) solutions replacing high-risk open-heart surgeries for treatment of heart valve diseases. Heart valve diseases are among the most serious cardiac complications affecting >12.7 million patients in Europe. Cardiac surgeons are urgently seeking for a low-risk minimally invasive solution to treat annually >300,000 patients with tricuspid heart valve disease, who are currently simply dying because of having no relevant therapeutic option. TRiCares has uniquely addressed technological challenges associated with tricuspid heart valve disease treatment- the company has developed the first-of-its-kind medical device for tricuspid heart valve replacement (TRICARIX) based on a proprietary dual-stent prosthesis platform.
The product addresses a fast-growing transcatheter heart valve replacement/repair market, that is driven by the increasing demand to treat heart valve diseases in the aging population. As no such solution is available for tricuspid valve, introduction of the TRICARIX will create a novel market segment with estimated total market potential of €1 billion in Europe only. The company’s strategy has been built along the regulatory route to obtain CE-marking for the TRICARIX medical device in 2021. TRiCares is led by experienced entrepreneur and experts with successful track record of bringing medical devices to market, including the first European transcatheter aortic valve replacement system in 2012. TRiCares seeks SMEInstr funding to reach the critical First-In-Man study milestone (total costs-of the project €4.3 million) that will greatly facilitate follow-up capital investments to finance the final large-scale efficacy/safety clinical study. CE-marking will position the product/company for a licensing agreement with a global medical device company to ensure effective marketing and clinical implementation of the device.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

TRICARES GMBH
Net EU contribution
€ 1 554 000,00
Address
HEISENBERGBOGEN 2
85609 Aschheim
Germany
SME
Yes
Region
Bayern Oberbayern München, Landkreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 346 250,00

Participants (1)